Clinical Trial

Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 1, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at 2, 4, 6 months of age.
Trial Details
NCT Number NCT06618196
Lead Sponsor LG Chem
Conditions Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type B Infection
Enrollment 336 participants
Start Date 2024-10-02
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-01